2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Review slidesets and expert analyses of key data from the 2020 Hematology Virtual Annual Meeting!

Lymphomas and Chronic Lymphocytic Leukemia

Capsule Summary Slidesets

CAR T-cell therapy lisocabtagene maraleucel yields ORR of 84% (CR rate of 66%) among patients with relapsed/refractory MCL with a 3% incidence of grade ≥ 3 CRS.

Released: December 8, 2020

Initial therapy with ibrutinib + venetoclax for 12 cycles resulted in a 1-year DFS rate of 95.3% in patients with uMRD who were subsequently randomized to placebo.

Released: December 14, 2020

5-year analysis of the phase III MURANO trial continued to demonstrate the efficacy of venetoclax + rituximab in patients with relapsed/refractory CLL.

Released: December 17, 2020

In ACE-CL-003, acalabrutinib plus venetoclax and an anti-CD20 antibody was generally well tolerated and yielded high CR/CRi and uMRD rates in both RR and TN CLL.

Released: December 15, 2020

Post hoc exploratory analysis identified potential predictors of response to tazemetostat in patients with relapsed/refractory follicular lymphoma with WT and mutant EZH2, including rituximab refractoriness.

Released: December 11, 2020

Umbralisib monotherapy associated with a 47% response rate in heavily pretreated patients with relapsed/refractory marginal zone lymphoma, follicular lymphoma, or small lymphocytic lymphoma.

Released: December 18, 2020

In a pooled analysis, cardiac AEs occurred in 17% of patients with CLL treated with acalabrutinib monotherapy a large majority of whom had preexisting risk factors.

Released: December 10, 2020

Parsaclisib active in BTK inhibitor–naive patients with R/R MZL across nodal, extranodal, or splenic subtypes.

Released: December 8, 2020

Durable CRs observed among patients with highly refractory FL and DLBCL, including those previously receiving CAR T-cell therapy.

Released: December 10, 2020

Among patients with cHL and a median age of 74 years, frontline brentuximab vedotin therapy was associated with ORR > 90%.

Released: December 14, 2020

Updated results of the next-generation, noncovalent BTK inhibitor LOXO-305 suggest encouraging efficacy and safety in heavily pretreated patients with CLL/SLL.

Released: December 17, 2020

In the phase III UNITY-CLL trial, umbralisib + ublituximab demonstrated superior PFS benefit vs chlorambucil + obinutuzumab in both previously untreated and previously treated patients with CLL.

Released: December 18, 2020

Lisocabtagene maraleucel plus ibrutinib well tolerated with encouraging efficacy in heavily pretreated patients with CLL/SLL.

Released: December 9, 2020

Axi-cel, a CD19-directed CAR T-cell therapy, produced high and durable response rates in patients with FL or MZL and ≥ 2 previous lines of therapy.

Released: December 18, 2020

Early-phase trial of mosunetuzumab suggests both high rates and durable responses in a cohort of patients with heavily pretreated FL, including in POD24 and double refractory disease.

Released: December 15, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue